Janssen’s latest move against Amgen highlights shifting pharma patent strategies
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect
Commission may face legal challenges but risks of trade secrets breaches and increased litigation abound
13 January 2023
The convergence of tech and biopharma has major implications for patent professionals
13 January 2023
The court rejected Juno Therapeutics’ appeal, despite claims of similarity with Amgen v Sanofi dispute
11 January 2023
Sales of drug earnings streams is an increasingly popular means of monetising life sciences innovations
10 January 2023
Patent litigation settlements face increasingly dangerous antitrust pitfalls
09 January 2023
Kathi Vidal will conduct a sua sponte review in Samsung vs Netlist and issued updates on VLSI IPR abuse reviews
06 January 2023
A similar, separate case this year may still trigger a change of course, however
06 January 2023
New allegations demonstrate a growing overlap between patent and trade secret disputes
05 January 2023
Purchase by Sino Biopharm subsidiary has been put on hold by US authorities
04 January 2023
Disputes over vaccine technology will continue to occupy headlines in 2023
03 January 2023
Unlock unlimited access to all IAM content